Navigation Links
Indication of considerable added benefit of vemurafenib in advanced melanoma
Date:1/8/2013

The drug vemurafenib (trade name Zelboraf) has been approved since February 2012 for the treatment of advanced melanoma (cancer of the skin cells that produce the dark pigment, melanin). It can be an option for adults whose melanoma cannot be removed by surgery or has formed secondaries (metastases) and in whose cancer a change (mutation) has occurred in a certain gene (BRAF-V600). The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, major advantages in terms of overall survival are accompanied by major potential harm in the form of side effects. Overall, there is an indication that vemurafenib offers considerable added benefit.

Vemurafenib in comparison with dacarbazine

The Federal Joint Committee (G-BA) has specified the drug dacarbazine as the appropriate comparator therapy. One study that compared vemurafenib directly with dacarbazine was available for the benefit assessment. This is a randomized and open-label study, i.e. patients were randomly assigned to one of the two treatment groups and both they and their doctors knew which of the two drugs was used in each case.

Longer survival means major added benefit

IQWiG always assesses a drug with a view to patient-relevant outcomes such as survival (mortality), symptoms and complications (morbidity) as well as quality of life. The study provides an indication that vemurafenib can prolong life. While half of the patients who received dacarbazine died after less than 10 months, in the vemurafenib group this was the case only after more than 13 months. The differing course of the two survival curves provides an indication of a major added benefit of vemurafenib.

Pain was the only outcome recorded in the study in relation to morbidity. There were, however, no statistically significant diff
'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
0049-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Antibody-coated stents: Indication of disadvantages
2. Abiraterone: Indication of considerable added benefit in certain patients
3. Considerable added benefit of ipilimumab in advanced melanoma
4. Marketing Xocolate International Corporation (MXI-Corp) Introduces Xe Healthy Energy Drink, A Rich And Delicious Antioxidant Beverage, Now Added to Xoçai™ Product Line
5. Capsiplex Plus Reviews for Improved Weight Loss Supplement Added to BestAppetiteSuppressantPills.com
6. UV-Aid Cold and Flu Prevention Added to List of Biomimicry Strategies on AskNature.Org
7. Healthy Chocolate Omega Squares, a Decedent Dark Chocolate Added to Marketing Xocolate International Corporation (MXI Corp) Product Lines
8. Rilpivirine for HIV: Added benefit for single agent proven
9. US Drug Watchdog Has Added Wright, Stryker, Biomet, and Zimmer To Their Initiative For All Metal Hip Implant Failures Victims & Offers Them The Names Of The Best Lawyers
10. CFO 911 Solutions' Charles K. Dargan II, CEO, and Reid Dabney, Managing Director Have Been Added to the Financial Entrepreneur Platform ("FEP") of Merriman Capital, Inc., a Wholly Owned Subsidiary of Merriman Holdings, Inc. (OTCQX: MERR)
11. Vandetanib in thyroid cancer: No proof of added benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... ... According to WFTV on July 15th heroin overdose rates have ... According to recent statistic Orlando suffers at least one death weekly as a direct ... and law enforcement officials are struggling to keep apace with its distribution. Officers rely ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... developing targeted biologics and biologic-device combination products for the treatment of bone disorders ... issued U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid ...
(Date:7/28/2015)... ... ... Women fear developing Alzheimer's disease more than having a heart attack or ... treatable, but there is little an individual can do to arrest the progress of ... trial, reports the July 2015 Harvard Women's Health Watch . , "There are ...
(Date:7/28/2015)... ... July 28, 2015 , ... A ... David Wright's Spinal Stenosis Injury" discussed baseball player David Wright’s spinal stenosis injury ... lumbar stenosis, brought on by degenerative changes in the spine, rather than congenital, ...
(Date:7/28/2015)... CO (PRWEB) , ... July 28, 2015 , ... There ... While most people think of highways, bridges and railroads, often overlooked is the over ... of our homes and buildings and into sewage treatment facilities. According to the ...
Breaking Medicine News(10 mins):Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3
... recent revelation that the chair of the board of ... executive until April 2010 sends an unfortunate message to ... priority, states an editorial http://www.cmaj.ca/cgi/doi/10.1503/cmaj.100850 in CMAJ ... simply no place for the tobacco industry on the ...
... Va., USA Today the International and American Associations for ... (JDR) remains the number one journal of 64 journal ... to the new 2009 Five-Year Scientific Impact Factor (SIF) rankings, ... shows that the JDR,s Five-Year SIF increased from 3.966 to ...
... ... ... As the leading voice for women and men facing infertility, RESOLVE: The National Infertility ... IntegraMed has for RESOLVE’s mission of patient support and education. , , ,“RESOLVE ...
... The most common was mistaking viral for bacterial infections, ... -- You,re not the only one who can,t always ... a bacterial infection that calls for antibiotics: Pediatricians say ... a new study shows. , Other common missed or ...
... The National Heart, Lung, and Blood Institute (NHLBI), part of ... to determine if the safety and efficacy of red blood ... been stored. One of the grants supports the first large, ... patients who receive transfusions of red blood cells that have ...
... ... Life One Year Later. , ... 19, 2010 -- Huntington, New York resident Roger Sencer was driving home from work in May ... seriously wrong, his wife Jane got him to Huntington Hospital. The news was not good: ...
Cached Medicine News:Health News:CMAJ calls for resignation of IDRC chair Barbara McDougall 2Health News:JDR increases its 5-Year SIF and remains number one dental journal of 64 in its category 2Health News:RESOLVE: The National Infertility Association Announces Partnership with Attain Fertility 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 3Health News:NHLBI funds research to improve safety of red blood cell transfusions 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 3Health News:NHLBI funds research to improve safety of red blood cell transfusions 4Health News:NHLBI funds research to improve safety of red blood cell transfusions 5Health News:NHLBI funds research to improve safety of red blood cell transfusions 6Health News:NHLBI funds research to improve safety of red blood cell transfusions 7Health News:3-D Brain Navigation, Minimally Invasive Surgery Combine to Help Neurosurgeon Remove Tennis Ball-Sized Tumor 2Health News:3-D Brain Navigation, Minimally Invasive Surgery Combine to Help Neurosurgeon Remove Tennis Ball-Sized Tumor 3
(Date:7/28/2015)... , July 28, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Human Insulin Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore more about ...
(Date:7/28/2015)... and LINCOLNSHIRE, Ill. , ... clinical laboratories to leverage business acumen on par with ... American Association of Clinical Chemistry (AACC) Annual Meeting & ... Beyond a Better Box™ to deliver a comprehensive and ... future unfolds. With advances in four key areas, Sysmex ...
(Date:7/28/2015)... SOUTH SAN FRANCISCO, Calif. , July 28, ... ) today announced that it will report its ... Tuesday, August 4, 2015.  Rigel senior management will ... and webcast at 4:30pm Eastern Time (1:30pm Pacific ... Participants can access the live conference call by ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5Sysmex Moves Beyond a Better Box 2Sysmex Moves Beyond a Better Box 3Sysmex Moves Beyond a Better Box 4Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2
... Pfizer said today that,results showing potential across numerous ... cell lung (NSCLC), colorectal,(CRC) and renal cell carcinoma ... will be presented next week at the American ... "Each person with cancer responds differently to treatment, ...
... /PRNewswire/ -- Phase II,results exceed expectations - Alchemia ... development company Alchemia Limited will,commence discussions with the ... conclusion of the Phase II clinical trial,of its ... data from the randomized Phase II clinical trial ...
Cached Medicine Technology:New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 2New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 3New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 4New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 5Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 2Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 3Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 4
The GENESIS II* Total Knee System will define the state of knee implants....
... system's curved-on-curved articulation maintains full inter-changeability. ... options for better patient fit. The ... spray porous coating, which offers an ... processed polyethylene is used for consistent, ...
... new generation of posterior stabilized knee ... the following: Patellar flange mates with ... machined condyles assure precise, repeatable kinematics ... and patella to reduce wear. Constant ...
... The TC-PLUS solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
Medicine Products: